ZA201600523B - Growth differentiation factor 15 (gdf-15) constructs - Google Patents
Growth differentiation factor 15 (gdf-15) constructsInfo
- Publication number
- ZA201600523B ZA201600523B ZA2016/00523A ZA201600523A ZA201600523B ZA 201600523 B ZA201600523 B ZA 201600523B ZA 2016/00523 A ZA2016/00523 A ZA 2016/00523A ZA 201600523 A ZA201600523 A ZA 201600523A ZA 201600523 B ZA201600523 B ZA 201600523B
- Authority
- ZA
- South Africa
- Prior art keywords
- constructs
- gdf
- differentiation factor
- growth differentiation
- gdf15
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 2
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860723P | 2013-07-31 | 2013-07-31 | |
| PCT/US2014/049254 WO2015017710A1 (en) | 2013-07-31 | 2014-07-31 | Growth differentiation factor 15 (gdf-15) constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201600523B true ZA201600523B (en) | 2024-10-30 |
Family
ID=51358091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/00523A ZA201600523B (en) | 2013-07-31 | 2016-01-25 | Growth differentiation factor 15 (gdf-15) constructs |
Country Status (35)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| JP2015182969A (ja) * | 2014-03-21 | 2015-10-22 | 四国化成工業株式会社 | トリアゾールシラン化合物、該化合物の合成方法及びその利用 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| KR102010652B1 (ko) * | 2017-08-21 | 2019-08-13 | 서울대학교병원 | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 |
| JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー／エス | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| EP3820900A1 (en) * | 2018-07-13 | 2021-05-19 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| MY205905A (en) | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| BR112021021271A2 (pt) * | 2019-04-23 | 2021-12-21 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15 |
| AU2020283890A1 (en) * | 2019-05-30 | 2021-12-16 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
| US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| KR102899743B1 (ko) * | 2019-12-11 | 2025-12-12 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| EP4081241A4 (en) * | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| US20230072226A1 (en) * | 2020-02-20 | 2023-03-09 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| EP4237438A4 (en) | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| KR20230044130A (ko) * | 2021-09-24 | 2023-04-03 | 바이오엔시스템스 주식회사 | Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도 |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| CN114835810B (zh) * | 2022-03-31 | 2024-01-05 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体及其应用 |
| EP4750799A1 (en) * | 2023-07-27 | 2026-06-03 | Binacea Pharma, Inc. | Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof |
| IL328216A (en) | 2023-11-17 | 2026-07-01 | Lilly Co Eli | Compounds for the treatment of diabetes or obesity |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| AU8591198A (en) * | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| MXPA01006922A (es) * | 1999-01-07 | 2002-04-24 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc. |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| CA2437958C (en) | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| JP4422949B2 (ja) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | ＴＧＦ−βスーパーファミリー産生・分泌促進剤 |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
| WO2004108157A2 (en) * | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| BRPI0406605B8 (pt) * | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| US20090042780A1 (en) * | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| AU2006315825A1 (en) * | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
| CN1974601A (zh) * | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | 一种新型Fc融合蛋白及其生产方法 |
| JP2010500876A (ja) * | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2279419A1 (en) | 2008-05-20 | 2011-02-02 | Roche Diagnostics GmbH | Gdf-15 as biomarker in type 1 diabetes |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| CA2740632A1 (en) * | 2008-10-31 | 2010-05-06 | St. Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| MX2012006397A (es) * | 2009-12-02 | 2012-11-30 | Amgen Inc | PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA. |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| ES2627337T3 (es) | 2010-08-26 | 2017-07-27 | F. Hoffmann-La Roche Ag | Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2012125850A1 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
| JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| EP3415528B1 (en) * | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9527927B2 (en) * | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| WO2013157953A1 (en) * | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| ES3066738T3 (en) | 2012-12-21 | 2026-05-14 | Aveo Pharmaceuticals Inc | Anti-gdf15 antibodies |
| CA2899170C (en) * | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
-
2014
- 2014-07-31 LT LTEP14752711.3T patent/LT3027642T/lt unknown
- 2014-07-31 BR BR112016002213A patent/BR112016002213A2/pt not_active Application Discontinuation
- 2014-07-31 MX MX2019012848A patent/MX387211B/es unknown
- 2014-07-31 TN TN2016000035A patent/TN2016000035A1/en unknown
- 2014-07-31 EP EP14752711.3A patent/EP3027642B1/en active Active
- 2014-07-31 MX MX2016001164A patent/MX369152B/es active IP Right Grant
- 2014-07-31 NZ NZ754961A patent/NZ754961A/en unknown
- 2014-07-31 UY UY0001035686A patent/UY35686A/es active IP Right Grant
- 2014-07-31 SI SI201431664T patent/SI3027642T1/sl unknown
- 2014-07-31 AR ARP140102882A patent/AR097181A1/es active IP Right Grant
- 2014-07-31 PE PE2016000103A patent/PE20160189A1/es unknown
- 2014-07-31 AP AP2016009011A patent/AP2016009011A0/xx unknown
- 2014-07-31 US US14/908,459 patent/US9862752B2/en active Active
- 2014-07-31 ES ES14752711T patent/ES2828670T3/es active Active
- 2014-07-31 JP JP2016531912A patent/JP6509852B2/ja active Active
- 2014-07-31 CN CN202110685579.XA patent/CN113527512A/zh active Pending
- 2014-07-31 AU AU2014296107A patent/AU2014296107B2/en active Active
- 2014-07-31 KR KR1020227008673A patent/KR102616674B1/ko active Active
- 2014-07-31 DK DK14752711.3T patent/DK3027642T3/da active
- 2014-07-31 WO PCT/US2014/049254 patent/WO2015017710A1/en not_active Ceased
- 2014-07-31 HU HUE14752711A patent/HUE050630T2/hu unknown
- 2014-07-31 MA MA38873A patent/MA38873B1/fr unknown
- 2014-07-31 EA EA201690297A patent/EA037355B1/ru not_active IP Right Cessation
- 2014-07-31 CA CA2918624A patent/CA2918624C/en active Active
- 2014-07-31 NZ NZ717030A patent/NZ717030A/en unknown
- 2014-07-31 SG SG11201600713RA patent/SG11201600713RA/en unknown
- 2014-07-31 PL PL14752711T patent/PL3027642T3/pl unknown
- 2014-07-31 UA UAA201601817A patent/UA116665C2/uk unknown
- 2014-07-31 CN CN201480043522.8A patent/CN105980400B/zh active Active
- 2014-07-31 KR KR1020237043685A patent/KR20240000642A/ko not_active Ceased
- 2014-07-31 KR KR1020167005421A patent/KR102376451B1/ko active Active
- 2014-07-31 EP EP20189041.5A patent/EP3763734A1/en active Pending
- 2014-07-31 TW TW103126283A patent/TWI648401B/zh active
- 2014-07-31 PT PT147527113T patent/PT3027642T/pt unknown
- 2014-07-31 EA EA202092386A patent/EA202092386A1/ru unknown
- 2014-08-03 JO JOP/2014/0240A patent/JO3566B1/ar active
-
2016
- 2016-01-24 IL IL243749A patent/IL243749B/en active IP Right Grant
- 2016-01-25 ZA ZA2016/00523A patent/ZA201600523B/en unknown
- 2016-01-29 PH PH12016500208A patent/PH12016500208A1/en unknown
- 2016-01-29 CL CL2016000249A patent/CL2016000249A1/es unknown
- 2016-02-29 CR CR20160097A patent/CR20160097A/es unknown
-
2017
- 2017-11-29 US US15/826,442 patent/US10894814B2/en active Active
-
2019
- 2019-04-02 JP JP2019070364A patent/JP6877478B2/ja active Active
-
2020
- 2020-10-09 CY CY20201100954T patent/CY1123836T1/el unknown
- 2020-11-11 US US17/094,968 patent/US20210079051A1/en not_active Abandoned
-
2021
- 2021-04-26 JP JP2021073836A patent/JP2021113219A/ja active Pending
-
2023
- 2023-06-16 JP JP2023099006A patent/JP2023116723A/ja active Pending
-
2024
- 2024-04-18 US US18/639,202 patent/US20240368236A1/en active Pending
- 2024-11-07 JP JP2024195157A patent/JP2025024032A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3566B1 (ar) | تركيبات عامل تمايز النمو 15 (gdf15) | |
| EP3683228A3 (en) | Growth differentiation factor 15 (gdf-15) polypeptides | |
| MX343729B (es) | Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos. | |
| JOP20200202A1 (ar) | اجسام مضادة بشرية لمستقبل الجلوكاجون | |
| WO2013033452A3 (en) | Fgf21 for use in treating type 1 diabetes | |
| NZ596037A (en) | Fgf21 mutants and uses thereof | |
| IN2015DN00397A (cg-RX-API-DMAC10.html) | ||
| MX2015008114A (es) | Derivados de exendina-4. | |
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| WO2012174534A3 (en) | Method of treating or ameliorating metabolic disorders using clec-2 | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| MX347372B (es) | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. | |
| PH12015502068A1 (en) | Treatment of insulin resistance associated with prolonged physical inactivity | |
| MX384123B (es) | Nutrición infantil para el mejoramiento en la sensibilidad a la insulina más adelante en la vida. | |
| MX2017016141A (es) | Producto a base de aguamiel de maguey para su uso en el control de la glucosa en personas con sindrome metabolico y/o diabetes. | |
| Zaharishchev | The Medical Profession Prestige: Deontological Aspect | |
| TH168762A (th) | สิ่งที่สร้างขึ้นเป็นโกรทดิฟเฟอเรนชิเอชันแฟคเตอร์ 15 (gdf-15) | |
| UA79751U (ru) | Способ прогнозирования течения заболевания у больных с первично-локализованной меланомой кожи | |
| JO3333B1 (ar) | استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه | |
| UA82795U (ru) | Способ оценки влияния электромагнитных излучений персональных компьютеров и мобильных телефонов на организм человека | |
| MX2008001011A (es) | Formulación auxiliar para el control de niveles altos de glucosa en sangre (hiperglicemia). |